Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Subprotocol Z1A: Binimetinib in NRAS-Mutated Tumors
NCT04439344Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib in lymphoma, solid tumor, multiple myeloma (MM), sponsored by National Cancer Institute. Started May 2016; status: active, not recruiting.
02
Drugs
binimetinib
03
Conditions
lymphomasolid tumormultiple myeloma (MM)
Beyond the preview
Go deeper on NCT04439344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439344.